First clinical data presented on latest technological advance in haemophilia a therapy

May 21, 2002

Seville, Spain, May 21, 2002 -The first recombinant Factor VIII therapy for Haemophilia A prepared entirely without the use of human- or animal-derived additives was found to be bioequivalent to the current gold-standard recombinant therapy according to data presented today at the XXV International Congress of the World Federation of Hemophilia.

Baxter's recombinant antihaemophilic Factor VIII protein-free method (rAHF/PFM), an investigational therapy currently in phase III clinical trials, is a new category of recombinant Factor VIII prepared entirely without the addition of any human or animal raw materials in the cell culture process, purification or final formulation.

Results from a randomized double-blind, cross-over study comparing rAHF/PFM and the control, Recombinate (recombinant antihaemophilic factor), indicate that rAHF/PFM and Recombinate rAHF are bioequivalent and should exhibit comparable hemostatic efficacy in the management of Haemophilia A.

rAHF/PFM is being developed in response to concerns about the theoretical transmission of currently unknown viruses or diseases through the continued use of human- or animal-derived components during the production process and final formulation.

All currently available recombinant Factor VIII therapies use human or animal-derived proteins at some point in their production processes or final product formulations. To date, more than 5 billion units of Recombinate rAHF have been supplied to the haemophilia community since the first clinical study infusion was administered in 1987, and there have been no confirmed cases of disease transmission associated with its use.

However, according to a recommendation from the Medical Advisory and Scientific Council (MASAC) of the National Hemophilia Federation, "all efforts should be made to remove human albumin from recombinant Factor VIII products. Moreover, increased efforts should be made to eliminate human and bovine proteins from the manufacturing process of recombinant Factor VIII products. "

Baxter's next generation recombinant Factor VIII, rAHF/PFM, was developed in response to this recommendation. "For the haemophilia community, having a Factor VIII concentrate produced without adding human or animal raw materials confers a greater comfort level about treatment," said Gordon Bray, MD, global medical director, Baxter BioScience. "The preparation of rAHF/PFM virtually eliminates the theoretical risk of disease transmission that may be associated with the use of human- or animal- derived raw materials or stabilizers."

rAHF/PFM was developed using a cell line derived from the one used for Recombinate production.

Haemophilia is caused by the absence or severe deficiency of Factor VIII, a protein in human blood critical for proper blood coagulation. More than approximately 350,000 people are living with haemophilia worldwide. Patients can experience spontaneous, uncontrolled internal bleeding that often is associated with pain, chronic joint destruction and, if left untreated, death.

People with haemophilia infuse themselves with clotting factors on average three times a month, unless they are on a preventative regimen, in which case they could infuse multiple times per week. Barring other complications or disorders, clinicians today expect a near normal life expectancy for patients, provided they receive proper treatment.
Baxter International Inc (NYSE: BAX) is a global health care company that, through its subsidiaries, provides critical therapies for people with life-threatening conditions. Baxter's bioscience, medication delivery and renal products and services are used to treat patients with some of the most challenging medical conditions including cancer, hemophilia, immune deficiencies, infectious diseases, kidney disease and trauma.

(Baxter and Recombinate are trademarks of Baxter International Inc. Baxter is registered in the U.S. Patent and Trademark Office.)

This news release contains forward-looking statements that involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, actions of regulatory bodies, the impact of competitive products and pricing, and other risks detailed in the company's filings with the Securities and Exchange Commission. These forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements.

Contact Information
Europe (on-site)
Nancy Lovre +44 77 14 504 224
Joanne Fensome +44 77 30 918 466
North America
Deborah Spak +1 847 948 2349 (media)
Neville Jeharajah +1 847 948 2875 (Investor)
Mary Kay Ladone +1 847 948 3371 (Investor)

Porter Novelli

Related Hemophilia Articles from Brightsurf:

A new cell & gene therapy approach to treat common bleeding disorder
WFIRM researchers have developed an optimized cellular platform for delivering Factor 8 to better treat patients with hemophilia A.

Early treatment linked to reduced joint damage in young adults with severe hemophilia A
Children with severe hemophilia A who receive early prophylaxis are less likely to have joint damage in young adulthood than those who begin treatment later, according to a new study in Blood Advances.

Hemophilia three times more prevalent than thought
For the World Federation of Hemophilia, Iorio assembled an international team of researchers from France, US and UK to perform a meta-analysis of the registry data in countries with the most comprehensive registries of hemophilia, which were Australia, Canada, France, Italy, New Zealand and the UK.

Gene-based factor VIIa prevents bleeding episodes in animals with hemophilia
Hematology researchers have further refined how a treatment currently used on an urgent basis to control bleeding in hemophilia patients holds promise as a preventive treatment as well.

Single injection treats hemophilia B for life, in proof-of-concept study
Salk researchers have demonstrated in mice that hemophilia B can be treated for life with one single injection containing disease-free liver cells that can produce their missing clotting factor.

Groundbreaking gene therapy trial set to cure hemophilia
A 'cure' for hemophilia is one step closer, following results of a groundbreaking gene therapy trial led by Queen Mary University of London and the NHS in London.

Inflammatory factors linked to inhibition of factor VIII gene therapy in hemophilia A
As a gene therapy cure for hemophilia A moves closer to reality, a new study sheds light on a challenging complication in which a host autoimmune response inhibits the production of normal clotting factor VIII from the transferred FVIII gene.

Spark Therapeutics and Pfizer announce publication in The New England Journal of Medicine of Interim Data from phase 1/2 clinical trial of investigational gene therapy for Hemophilia B
Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc.

Disruptive technology for the treatment of hemophilia
An international team of hematologists including Guy Young, MD, of Children's Hospital Los Angeles, has found that in patients with hemophilia A with inhibitors, a novel therapy called emicizumab, decreases incidence of bleeding episodes by 87 percent.

Researchers improve vbectors for delivering hFVIII gene therapy to treat Hemophilia A
A new study examined 42 combinations of promoters and enhancers for human factor VIII (hFVIII) gene expression to identify the optimal adeno-associated virus (AAV)-based gene therapy delivery vector constructs to take forward into development.

Read More: Hemophilia News and Hemophilia Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to